2025
Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services
Cohen S, Straus E, Fiellin D, Pomeranz J, Suzuki J, Tetrault J, Weimer M, Edelman E, Joudrey P. Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services. JAMA Network Open 2025, 8: e2526077. PMID: 40773194, PMCID: PMC12332638, DOI: 10.1001/jamanetworkopen.2025.26077.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCross-Sectional StudiesDose-Response Relationship, DrugDrug Administration ScheduleFemaleFentanylHospitals, TeachingHumansMaleMethadoneMiddle AgedNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPhysician ExecutivesPractice Guidelines as TopicReferral and ConsultationSurveys and QuestionnairesUnited StatesConceptsInitiation of methadoneAddiction consult servicesMethadone initiationBuprenorphine initiationOpioid use disorderHigh dosesLow dosesAddiction medicineLow-dose initiationFull-agonist opioidsUp-titrationCross-sectional survey studyInitiation regimenFentanyl usePrimary outcomeDay 1OpioidBuprenorphineHospital-based practiceUse disorderClinical casesClinical guidelinesMethadoneSynthetic opioidsDose[18F]SynVesT-1 PET Detects SV2A Changes in the Spinal Cord and Brain of Rats with Spinal Cord Injury
Chen B, Zheng C, Balayeva T, Toyonaga T, Wang X, Tong J, Mennie W, Mihailovic J, Coman D, Hyder F, Strittmatter S, Carson R, Huang Y, Cai Z. [18F]SynVesT-1 PET Detects SV2A Changes in the Spinal Cord and Brain of Rats with Spinal Cord Injury. Journal Of Nuclear Medicine 2025, 66: 1440-1448. PMID: 40675757, PMCID: PMC12410297, DOI: 10.2967/jnumed.124.269291.Peer-Reviewed Original ResearchConceptsSpinal cord injuryDistribution volume ratioDiffusion tensor imagingSpinal cordRat modelDay 1SUV ratioImmunohistochemical stainingSham controlsDay 9PET imagingRat model of spinal cord injuryContusion SCI rat modelSpinal cord injury ratsModel of spinal cord injuryCord injuryWestern blottingModerate contusion injuryBrain of ratsDiffusion tensor imaging analysisPost-mortem spinal cordTraumatic spinal cord injurySCI rat modelSynaptic vesicle glycoprotein 2ACervical cordDerivation and Validation of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes With Prognostic Relevance
Stanski N, Zhang B, Ouyang J, Sanchez-Pinto L, Faustino E, Rogerson C, Hall M, Weiss S, Bennett T, Standage S, Goldstein S, Liu K. Derivation and Validation of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes With Prognostic Relevance. Pediatric Critical Care Medicine 2025, 26: e1084-e1095. PMID: 40637493, PMCID: PMC12252218, DOI: 10.1097/pcc.0000000000003789.Peer-Reviewed Original ResearchConceptsSepsis-associated acute kidney injuryRetrospective observational studyPoor outcomeLaboratory evidenceLaboratory evidence of inflammationContinuous renal replacement therapyAKI subphenotypesPatients aged 0Renal replacement therapyAcute kidney injuryEvidence of inflammationClinical trial enrollmentOdds of mortalityAcid-base derangementsPersistent AKIPrognostic relevanceReplacement therapyKidney injurySeptic shockSubphenotype 2Derivation cohortValidation cohortWorse outcomesPediatric sepsisDay 1The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
Bhakuni R, Hall E, Ansstas G, Bhatia S, Brohl A, Burgess M, Dimitrova M, Gao L, Ishizuka J, Lipson E, Lutzky J, Silk A, Yun J, Brownell I, Murray J, Mowery Y, Gooley T, Gore S, Topalian S, Nghiem P. The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps9598.Peer-Reviewed Original ResearchMerkel cell carcinomaProgression-free survivalCell carcinomaProgressive diseaseATR inhibitionDay 1PD-1 pathway inhibitorsRare neuroendocrine skin cancerRecommended phase II doseAnti-tumor immune responseTreatment-emergent adverse eventsKi-67 proliferative indexPD-(L)1 blockadePhase II doseResponse Evaluation CriteriaPhase II studySolid tumor immunotherapyInduce tumor regressionNeuroendocrine skin cancerPhase I trialLog-rank testMerkel cell polyomavirusHigh response rateCell cycle checkpoint regulationII doseComparison of Posterior Quadratus Lumborum Block vs Surgical Wound Infiltration in Patients Undergoing Bariatric Sleeve Gastrectomy Surgery
Shariat A, Kadakia R, Lin H, Egorova N, Jin S, Latmore M, Epstein J, Pai B.H P, Park K, Kini S, Bhatt H. Comparison of Posterior Quadratus Lumborum Block vs Surgical Wound Infiltration in Patients Undergoing Bariatric Sleeve Gastrectomy Surgery. Obesity Surgery 2025, 35: 2673-2679. PMID: 40404913, DOI: 10.1007/s11695-025-07934-1.Peer-Reviewed Original ResearchPosterior quadratus lumborum blockLaparoscopic sleeve gastrectomySurgical wound infiltrationPostoperative opioid consumptionVAS pain scoresPostoperative day 1Quadratus lumborum blockWound infiltrationPain scoresRandomized pilot studyOpioid consumptionLocal anestheticsDay 1Decreased postoperative opioid consumptionVisual analog pain scorePostoperative VAS pain scoresInfiltration of local anestheticWound infiltration groupAnalog pain scoresASA 3 patientsPostoperative analgesic medicationPostoperative day 2Incidence of nauseaSleeve gastrectomy surgeryMorphine equivalentsFeasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Scott S, Roberts D, Gupta V, Joseph N, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clinical Lymphoma Myeloma & Leukemia 2025, 25: 656-660. PMID: 40345961, DOI: 10.1016/j.clml.2025.04.002.Peer-Reviewed Original ResearchStep-up dosingRelapsed/Refractory Multiple MyelomaTarget doseInstitutional protocolRelapsed/refractory multiple myeloma patientsBispecific antibodiesTreatment of patientsProtocol eligibilityMultiple myelomaT cellsAccelerated approvalToxicity managementLower hospitalization ratesDay 1Low incidenceFDA labelingPatientsCare centerPatient's diseaseNeurological changesHospitalization ratesDoseOral abstractsTocilizumabHospitalSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2024
Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab. Blood 2024, 144: 7004-7004. DOI: 10.1182/blood-2024-199190.Peer-Reviewed Original ResearchTwice-weekly bortezomibTwice-weekly groupTwice-weekly dosingWeekly bortezomibMultiple myelomaPeripheral neuropathyBortezomib doseTwice-weeklyFrontline treatmentRate of PNDay 1Rates of peripheral neuropathyMedian follow-up timeTreatment efficacyBortezomib-induced peripheral neuropathyResponse rateWeeks groupBortezomib dose reductionBortezomib-containing regimensBortezomib-induced PNDose of bortezomibDiagnosis of MMIncidence of PNSingle-center studyFollow-up timeLidocaine patches after cesarean sections: a randomized control trial
Arkfeld C, Starosta A, Esencan E, Athens Z, Lundsberg L, Merriam A. Lidocaine patches after cesarean sections: a randomized control trial. American Journal Of Obstetrics & Gynecology MFM 2024, 6: 101536. PMID: 39491590, DOI: 10.1016/j.ajogmf.2024.101536.Peer-Reviewed Original ResearchPost-operative pain scoresLidocaine patch groupVisual analog scalePost-operative day 1Pain scoresLidocaine patchCesarean sectionAnalog scalePatch groupDay 1Post-cesarean pain managementPost-operative hospital stayVisual analog pain scoreDay 3Day 2Day 4Controlled TrialsControlled trials of patientsAnalog pain scoresBaseline maternal characteristicsTrial of patientsOpiate use disorderPain management strategiesPost-operative periodAbdominal hernia repair640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1Water-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisDermatitisPrescription productsTrialsDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Philip P, Sahai V, Bahary N, Mahipal A, Kasi A, Lima C, Alistar A, Oberstein P, Golan T, Metges J, Lacy J, Fountzilas C, Lopez C, Ducreux M, Hammel P, Salem M, Bajor D, Benson A, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal Of Clinical Oncology 2024, 42: 3692-3701. PMID: 39088774, DOI: 10.1200/jco.23.02659.Peer-Reviewed Original ResearchMetastatic pancreatic adenocarcinomaOverall survivalCPI-613Randomized phase III trialTreatment-emergent adverse eventsExperimental armDifficult-to-treat diseaseFavorable performance statusProgression-free survivalTreatment naive patientsFirst-line therapyPhase I studyPhase III trialsMedian OSMetastatic adenocarcinomaIII trialsFirst-linePerformance statusPancreatic adenocarcinomaAdverse eventsDevimistatDay 1Disease progressionControl armPatientsTinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink
Yih W, Duffy J, Su J, Bazel S, Fireman B, Hurley L, Maro J, Marquez P, Moro P, Nair N, Nelson J, Smith N, Sundaram M, Vasquez-Benitez G, Weintraub E, Xu S, Shimabukuro T. Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink. American Journal Of Otolaryngology 2024, 45: 104448. PMID: 39096568, PMCID: PMC11634645, DOI: 10.1016/j.amjoto.2024.104448.Peer-Reviewed Original ResearchVaccine Adverse Event Reporting SystemVaccine Safety DatalinkReports of tinnitusInfluenza vaccineAdverse Event Reporting SystemEvent Reporting SystemCOVID-19 vaccineIncreased risk of tinnitusIncidence rateRisk of tinnitusVaccine safety surveillance systemOccurrence of tinnitusEmpirical Bayesian data miningCOVID-19 vaccine dosesDay 1Increased riskTinnitusVaccine doseInfluenzaConfounding factorsDisproportionate reportingSafety surveillance systemMedical visitsVaccineAge groupsPembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial
Dzienis M, Cundom J, Fuentes C, Spreafico A, Nordlinger M, Pastor A, Alesi E, Neki A, Fung A, Lima I, Oppelt P, da Cunha G, Burtness B, Franke F, Tseng J, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. Journal Of Clinical Oncology 2024, 42: 2989-2999. PMID: 39038265, PMCID: PMC11361359, DOI: 10.1200/jco.23.02625.Peer-Reviewed Original ResearchBlinded independent central reviewRecurrent/metastatic head and neck squamous cell carcinomaHead and neck squamous cell carcinomaNeck squamous cell carcinomaR/M HNSCCSquamous cell carcinomaRECIST v1.1Cell carcinomaSingle-armStandard-of-care first-line treatmentSafety of first-line pembrolizumabEastern Cooperative Oncology Group performance statusDay 1Treatment-related adverse eventsAlternative chemotherapy combinationsFirst-line pembrolizumabPD-L1 statusMedian Follow-UpFirst-line therapyIndependent central reviewFirst-line treatmentPhase IV trialChemotherapy combinationsComplete responsePD-L1Itch and Pain Behaviors in Irritant Contact Dermatitis Produced by Sodium Lauryl Sulfate in Mice
Malewicz-Oeck N, Zhang Z, Shimada S, LaMotte R. Itch and Pain Behaviors in Irritant Contact Dermatitis Produced by Sodium Lauryl Sulfate in Mice. International Journal Of Molecular Sciences 2024, 25: 7718. PMID: 39062959, PMCID: PMC11276812, DOI: 10.3390/ijms25147718.Peer-Reviewed Original ResearchIrritant contact dermatitisDay 1Heat stimuliSkin inflammationSigns of spontaneous painContact dermatitisHyperalgesia-like behaviorResponses to pruritogensPain-like behaviorsSodium lauryl sulfateCompared to salineMeasurement of skin thicknessSpontaneous painIncreased skin thicknessHistamine-dependentPain behaviorCutaneous inflammationScratching boutsMouse modelPainSkin thicknessItchingInflammationMiceDay 0Music during cataract surgery: effect on anxiety
Rivera P, Linderman W, Miguez S, Chow J, DeBroff B, Diaz V. Music during cataract surgery: effect on anxiety. Journal Of Cataract & Refractive Surgery 2024, 50: 688-692. PMID: 38499999, DOI: 10.1097/j.jcrs.0000000000001444.Peer-Reviewed Original ResearchMusic groupPatient-selected musicPatient's self-reported anxietyLikert-style surveyCataract surgeryMusicPaired t-testPatient experienceSelf-reported anxietyControl groupPatient anxietyNo significant differenceDecreased anxietyBaseline anxietyDosage of sedationControlled clinical trialsSignificant differenceAnxietySedative injectionT-testPostoperative day 1Low-risk methodIntra-operativelyClinical trialsDay 1292-OR: Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction–Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets
SAKUMA I, GASPAR R, NASIRI A, KAHN M, GUERRA M, YIMLAMAI D, MURRAY S, PERELIS M, BARNES W, VATNER D, PETERSEN K, SAMUEL V, SHULMAN G. 292-OR: Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction–Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets. Diabetes 2024, 73 DOI: 10.2337/db24-292-or.Peer-Reviewed Original ResearchCholine-deficient l-amino acid-defined high-fat dietAccumulation of cholesterolMRNA expressionPlasma ALTL-amino acid-defined high-fat dietProtective effectLiver lipid dropletsType 2 diabetesPotential therapeutic approachHigh-fat dietDecreased plasma ALTFibrosis markersFree cholesterol accumulationLipid dropletsLiver inflammationDay 1Macrophage markersHepatic inflammationMouse modelMarker expressionTherapeutic approachesDay 2Day 3Day 7FibrosisVonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, Harris T, Hunt B, Fass R, Katz P. Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. Clinical Gastroenterology And Hepatology 2024, 22: 2211-2220.e10. PMID: 38750866, DOI: 10.1016/j.cgh.2024.05.004.Peer-Reviewed Original ResearchNon-erosive reflux diseaseHeartburn-free daysErosive esophagitisReflux diseaseRandomized trialsActive-treatment extensionRandomized to placeboPotassium-competitive acid blockerPlacebo-controlled periodDays of therapyPercentage of subjectsPrimary endpointPercentage of daysHeartburn symptomsPlaceboVonoprazanAcid blockerNighttime heartburnDay 1Randomized subjectsDocumented efficacyStudy armsDay 2Adult subjectsExtension periodPaediatric laceration repair in the emergency department: post-discharge pain and maladaptive behavioural changes
Martin S, Heyming T, Fortier M, Kain Z. Paediatric laceration repair in the emergency department: post-discharge pain and maladaptive behavioural changes. Emergency Medicine Journal 2024, 41: emermed-2023-213858. PMID: 38724104, PMCID: PMC11262956, DOI: 10.1136/emermed-2023-213858.Peer-Reviewed Original ResearchWeeks post-dischargePost-discharge recoveryPost-dischargePost-discharge painMaladaptive behavioral changesBehavioral changesDay 1Laceration repairAssociated with incidencePainful medical proceduresLonger length of stayLogistic regression analysisChildren's painPaediatric EDConvenience sampleED dischargeLength of stayHigher painPain managementPerioperative researchEmergency departmentChildren 2Mild levelProcedural painExtremity lacerationsSevere, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions.
Namineni N, Waldron C, Tormey C, Goshua G. Severe, Refractory Primary Warm Autoimmune Hemolytic Anemia Requiring 90 Erythrocyte Transfusions. Annals Of Internal Medicine Clinical Cases 2024, 3 PMID: 38725710, PMCID: PMC11081177, DOI: 10.7326/aimcc.2023.1141.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaAutoimmune hemolytic anemiaHemolytic anemiaSevere warm autoimmune hemolytic anemiaMonths of follow-upHealthy 60-year-old manTherapeutic plasma exchangeHospital day 1Erythrocyte transfusionTransfusion-DependentRefractory diseasePlasma exchangeImmune globulinHospital stayFollow-upDay 1AnemiaHospitalRituximabReticulocytopeniaRemissionSplenectomyTransfusionPatientsStayIntegrating population and single-cell variations in vaccine responses identifies a naturally adjuvanted human immune setpoint
Mulè M, Martins A, Cheung F, Farmer R, Sellers B, Quiel J, Jain A, Kotliarov Y, Bansal N, Chen J, Schwartzberg P, Tsang J. Integrating population and single-cell variations in vaccine responses identifies a naturally adjuvanted human immune setpoint. Immunity 2024, 57: 1160-1176.e7. PMID: 38697118, DOI: 10.1016/j.immuni.2024.04.009.Peer-Reviewed Original ResearchConceptsTranscriptional statesVaccine responseSingle-cell profiling methodsSingle-cell variationAS03-adjuvanted vaccineUnadjuvanted influenza vaccineResponse to lipopolysaccharide stimulationB cell signaturesCD14<sup>+</sup> monocytesSingle-cell levelBiological insightsUnadjuvanted vaccineAS03-adjuvantedInfluenza vaccineResponse phenotypesCITE-seqInnate subsetsAdjuvant developmentHigh antibody respondersDay 1Antibody respondersLipopolysaccharide stimulationVaccineCorrelation networkHuman population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply